Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.
Pellegrino B, Capoluongo ED, Bagnoli M, Arenare L, Califano D, Scambia G, Cecere SC, Silini EM, Scaglione GL, Spina A, Tognon G, Campanini N, Pisano C, Russo D, Pettinato A, Scollo P, Iemmolo R, De Cecco L, Musolino A, Marchini S, Beltrame L, Paracchini L, Perrone F, Mezzanzanica D, Pignata S. Pellegrino B, et al. Among authors: musolino a. ESMO Open. 2025 Jan 3;10(1):104091. doi: 10.1016/j.esmoop.2024.104091. Online ahead of print. ESMO Open. 2025. PMID: 39754985 Free article.
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, Serra V, Scaglione GL, Spina A, Cecere SC, De Cecio R, Normanno N, Colombo N, Lorusso D, Russo D, Nardelli C, D'Incalci M, Llop-Guevara A, Pisano C, Baldassarre G, Mezzanzanica D, Artioli G, Setaro M, Tasca G, Roma C, Campanini N, Cinieri S, Sergi A, Musolino A, Perrone F, Chiodini P, Marchini S, Pignata S. Capoluongo ED, et al. Among authors: musolino a. ESMO Open. 2022 Oct;7(5):100585. doi: 10.1016/j.esmoop.2022.100585. Epub 2022 Sep 23. ESMO Open. 2022. PMID: 36156447 Free PMC article. Clinical Trial.
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A. Pellegrino B, et al. Among authors: musolino a. ESMO Open. 2021 Feb;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. Epub 2020 Dec 31. ESMO Open. 2021. PMID: 33399082 Free PMC article. Clinical Trial.
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, Silini EM, Campanini N, Barbieri E, Zamagni C, Degli Esposti R, Cortesi L, Bisagni G, Cavanna L, Frassoldati A, Sgargi P, Michiara M. Musolino A, et al. Eur J Cancer. 2018 Jan;88:10-20. doi: 10.1016/j.ejca.2017.10.024. Epub 2017 Nov 23. Eur J Cancer. 2018. PMID: 29175735
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.
Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, Uliana V, Zanoni D, Tommasi C, Bortesi B, Bonatti F, Piacentini F, Cortesi L, Camisa R, Sgargi P, Michiara M, Musolino A. Viansone A, et al. Among authors: musolino a. Breast. 2022 Oct;65:145-150. doi: 10.1016/j.breast.2022.07.012. Epub 2022 Jul 31. Breast. 2022. PMID: 35970028 Free PMC article.
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Fiorentini G, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Marchetti P, Melegari E, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Saracchini S, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V; VICTOR Study Group. Cazzaniga ME, et al. Among authors: musolino a. Breast. 2019 Dec;48:7-16. doi: 10.1016/j.breast.2019.07.006. Epub 2019 Aug 22. Breast. 2019. PMID: 31470257
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V. Dieci MV, et al. Among authors: musolino a. Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007. Ann Oncol. 2019. PMID: 30657852 Free PMC article. Clinical Trial.
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G, Boni C. Bisagni G, et al. Among authors: musolino a. Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7. doi: 10.1007/s00280-013-2100-6. Epub 2013 Feb 3. Cancer Chemother Pharmacol. 2013. PMID: 23377310 Clinical Trial.
223 results